CAI - Company ID 0002019410
The table below shows Caris Life Sciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 |
|---|---|---|---|
| Cash & equivalents | $819.90M | $753.22M | $718.93M |
| Short-term investments | $2.31M | $2.27M | $2.25M |
| Receivables | $90.52M | $26.70M | $50.89M |
| Inventory | - | - | - |
| Total current assets | $1.01B | $854.25M | $833.32M |
| Property, plant & equipment | $82.67M | $64.00M | $61.31M |
| Goodwill | $19.34M | $19.34M | $19.34M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total assets |
| $1.16B |
| $984.57M |
| $955.06M |
| Accounts payable | $69.80M | $29.00M | $28.73M |
| Total current liabilities | $143.90M | $86.03M | $90.18M |
| Long-term debt | $381.40M | $376.30M | $373.61M |
| Total liabilities | $568.90M | $506.21M | $502.15M |
| Retained earnings | -$2.55B | -$2.63B | -$2.66B |
| Total equity | $593.49M | $478.36M | $452.90M |